Research & Development
Ovarian Adnexal Mass
Aspira announces commercial launch of blood-based ovarian cancer risk assay
OvaWatch uses a proprietary algorithm and seven biomarkers, combined with individual risk factors such as menopause status, to assess risk of malignancy, with a negative predictive value of 99%.
November 30, 2022
Aspira Women's Health, BioReference to distribute blood tests to detect the risk of ovarian malignancy
The firms will co-market and distribute Aspira's Ova1Plus, which combines its Ova1 and Overa blood tests to detect the risk of ovarian malignancy in women with adnexal masses prior to surgery.
October 5, 2022
Aspira promotes OvaWatch clinical trial results
The study highlights OvaWatch's potential for accurately assessing the risk of ovarian malignancy in patients with pelvic masses, according to Aspira.
June 16, 2022
Page 1 of 1